AzTrials
AzTrials

ALS (Amyotrophic Lateral Sclerosis)NCT07067229

Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease

A study testing Personalized rTMS and Standard rTMS in people with ALS (Amyotrophic Lateral Sclerosis), run by Chulalongkorn University at 1 site in Thailand.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
ALS (Amyotrophic Lateral Sclerosis)
What is being tested?
Personalized rTMS and Standard rTMS
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteThailand
Study dates
1 Aug 2025to 30 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants aged between 18 and 80 years
  • Diagnosed with any type of motor neuron disease (MND)
  • Have mild to moderate severity, as assessed by the Sinaki-Mulder scale, with a severity level between 1 and 3

Who cannot join

  • History of other neurological disorders, such as stroke
  • Use of ventilatory support
  • Severe dementia

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jakkrit Amornvit, MD contact

Thailand: 88-951-9195

jakkrit.a@chula.ac.th

Phunsuk Kantha, PT.,PhD contact

Thailand: 93-295-1646

phunsuk.kan@mahidol.ac.th

Thailand1 site, 1 recruiting
  • King Chulalongkorn Memorial hospital, The Thai Red Cross Society

    Bangkok, Pathumwan, 10330

    Jakkrit Amornvit, MD, +66622169338, jakkrit.a@chula.ac.th

    Phuettha Sangrut, MSc, 6622564000 ext. 80722, phuettha.s@chulahospital.org

    Recruiting

Other trials in Thailand

About this study

Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure. This study aims to develop a novel treatment approach combining personalized repetitive transcranial magnetic stimulation (rTMS) with mixed reality (MR) exercise-based games (exergames) to slow disease progression and improve quality of life. In this randomised controlled trial study will compare three groups: (1) rTMS with MR exercise (personalized intervention), (2) rTMS with MR exercise (standard intervention), and (3) sham rTMS with MR exercise. Outcomes will be assessed at baseline, 3 months, and 6 months post intervention. The long-term goal is to implement this approach in clinical settings to enhance care for people with MND.

Read the detailed description

After screening process, eligible participants will be invited to visit Chula Neuroscience Center for the baseline assessments which will take proximately 2 hours.

The baseline assessments will be as follow:

  1. Demographic information such as age, sex, body height, body weight, body mass index, date of diagnosis, type of MND, and current medications.
  2. Questionnaires including amyotrophic lateral sclerosis functional rating scale - revised version (ALSFRS-R), penn upper motor neuron score (PUMNS), patient health questionnaire (PHQ-9), and EuroQol 5-Dimension 5-level (EQ-5D-5L).
  3. Clinical assessments including hand grip test, pinch grip test, and hand function.
  4. Lung function tests such as forced vital capacity (FVC).
  5. Neurophysiological assessment by using transcranial magnetic stimulation (TMS)
  6. Electromyography (EMG) including compound muscle action potential (CMAP), motor unit number estimation (MScan fit-MUNE), and motor unit number index (MUNIX).
  7. Magnetic resonance imaging (MRI)
Being tested
Personalized rTMS, Standard rTMS, Sham rTMS
Keywords
Amyotrophic Lateral Sclerosis, Transcranial Magnetic Stimulation, Intervention, Augmented Reality
Medical subject headings
Amyotrophic Lateral Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personalized rTMSDevice

    Personalized repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise

  • Standard rTMSDevice

    Standard repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise

  • Sham rTMSDevice

    Sham rTMS together with mixed-reality (MR) exercise

Study groups in NCT07067229
Study groupRoleWhat they receive
Personalized intervention groupExperimentalParticipants will receive personalised repetitive transcranial magnetic stimulation mixed reality.
Receives: Device: Personalized rTMS
Standard intervention groupActive comparatorParticipants will receive standard repetitive transcranial magnetic stimulation plus mixed reality.
Receives: Device: Standard rTMS
Sham groupSham comparatorParticipants will receive sham repetitive transcranial magnetic stimulation mixed reality.
Receives: Device: Sham rTMS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Amyotrophic Lateral Sclerosis Functional rating scale - revised version (ALSFRS-R)

    The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) is a 12-item questionnaire used to assess functional ability in people with ALS across four domains: bulbar, fine motor, gross motor, and respiratory function. Each item is scored from 0 (unable) to 4 (normal), with a total score ranging from 0 to 48. It can be self-reported or clinician-administered in person, by phone, or online. Lower scores indicate greater disability. The ALSFRS-R is used to monitor disease progression and guide clinical care.

    Measured: ALSFRS-R will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  2. Muscle evoke potential (MEP)

    Participants will be stimulated at the primary motor cortex by transcranial magnetic stimulation to measure cortical excitability, which sends the motor outputs to Tibialis Anterior (TA) and Abductor Pollicis Brevis (APB) muscles. The MEP will be used to assess muscle activity in these muscles during the stimulation. The MEP will be measured in mV.

    Measured: MEP will be mesured at three time points (baseline, 3-month, and 6-month post intervention).

  3. Motor unit number estimation (MScan fit-MUNE)

    For MScan fit-MUNE, CMAP is recorded at multiple stimulation intensities. The MScan fit-MUNE software then generates a curve representing the relationship between stimulation intensity and CMAP amplitude. A mathematical model is fitted to this curve to estimate the number of motor units contributing to the generation of the CMAP.

    Measured: MScan fit-MUNE will be mesured at three time points (baseline, 3-month, and 6-month post intervention).

  4. Motor unit number index (MUNIX)

    For MUNIX (Motor Unit Number Index), the procedure begins with recording the CMAP. Then, the participant is asked to gently contract the muscle. During this contraction, the interference pattern of muscle electrical activity is recorded. The MUNIX value is calculated by analyzing the ratio between the CMAP amplitude and the amplitude of the interference pattern. This provides an estimate of motor unit function.

    Measured: MUNIX will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  5. Cortical silent period (CSP)

    Participants will be stimulated at the primary motor cortex by transcranial magnetic stimulation to measure cortical excitability, which sends the motor outputs to Tibialis Anterior (TA) and Abductor Pollicis Brevis (APB) muscles. The CSP will be used to assess muscle activity in these muscles during the stimulation. The CSP will be measured in ms.

    Measured: Muscle evoke potential will be measured at three time points (baseline, 3-month, and 6-month post intervention).

Secondary outcomes (11)
  1. Muscle mass

    We will used the bioelectrical impedance analysis (BIA), which is a method used for measuring body composition.Participants will be asked to step on to the BIA device, placing their feet on the foot electrodes. The muscle mass will be recored in kilograms.

    Measured: Muscle mass will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  2. Body mass index (BMI)

    We will used the bioelectrical impedance analysis (BIA), which is a method used for measuring body composition.Participants will be asked to step on to the BIA device, placing their feet on the foot electrodes. The BMI will be recored in kg/m^2.

    Measured: BMI will be measured at three time point (baseline, 3-month, 6-month post intervention).

  3. Hand grip test

    The Hand Grip Test is an objective measure of isometric grip strength, commonly used to assess overall muscle strength and functional status. The test is performed using a handheld dynamometer, which the participant squeezes with maximum effort, typically while seated with the elbow at a 90-degree angle. The test is usually repeated three times per hand, and the highest or average value measured in kilograms is recorded. Lower grip strength is associated with reduced physical function and is often used as an indicator of frailty, sarcopenia, or neuromuscular decline.

    Measured: Hand grip test will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  4. Pinch grip test

    The Pinch Grip Test is used to assess the strength of the thumb muscles in individuals with motor neuron disease (MND). Participants are asked to hold a pinch grip dynamometer with their arm positioned at a 90-degree angle and squeeze as hard as possible for 3 to 5 seconds. Each set consists of 10 repetitions, and the test includes 5 sets in total, with a 1-minute rest between sets. The goal is to measure the maximum force generated during the test. Afterward, participants are instructed to maintain a pinch force at 50% ± 5% of their maximum strength for as long as possible. Results are recorded in kilograms (kg) and duration (seconds).

    Measured: Pinch grip test will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  5. Hand function

    Hand function will be assessed using the Wolf Motor Function Test (WMFT) to evaluate gross motor movements, such as placing the hand on a table, placing the arm on a box, and extending the arm. The Jebsen-Taylor Test of Hand Function will be used to assess fine motor movements, such as picking up objects, grasping a can, and handling a paperclip. The outcomes will be recorded as the time taken to complete each task.

    Measured: Hand function will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  6. Penn upper motor neuron score (PUMNS)

    The PUMNS is a questionnaire used to assess neurological responses (reflexes) and spasticity in individuals with motor neuron disease (MND). It helps evaluate the severity of the disease and monitor changes in the patient's nervous system. The researcher will assess various reflexes and signs of spasticity, such as Hoffman's sign and Babinski's sign.

    Measured: PUMNS will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  7. Patient health questionnaire (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a widely used self-report screening tool for assessing the presence and severity of depression. It consists of 9 items, each corresponding to one of the diagnostic criteria for major depressive disorder as defined by the DSM-IV. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Measured: PHQ-9 will be measured at three time points (baseline, 3-month, and 6-month).

  8. EuroQol 5-Dimension 5-level (EQ-5D-5L)

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) is a standardized questionnaire used to measure health-related quality of life (HRQoL). It is widely used in clinical, public health, and economic evaluations to assess the overall health status of individuals. The EQ-5D-5L includes two parts: 1) Descriptive System whhich assesses health across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and 2) EQ Visual Analogue Scale (EQ VAS - A vertical scale ranging from 0 (worst imaginable health) to 100 (best imaginable health) on which the respondent rates their overall health.

    Measured: EQ-5D-5L will be measure at three time ponts (baseline, 3-month, and 6-months post intervention).

  9. Forced vital capacity (FVC)

    Forced Vital Capacity (FVC) is a key measure of lung function that assesses the amount of air a person can forcefully exhale after taking the deepest possible breath. It is measured in litres (L) using a device called a spirometer.

    During the test, the person inhales fully and then exhales as hard and fast as possible until no more air can be expelled. The total volume of air exhaled is recorded as the FVC. This test helps evaluate lung capacity and is commonly used to monitor respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and motor neuron disease (MND).

    Measured: FVC will be measured at three time points (baseline, 3-month, and 6-month post intervention).

  10. Magnetic resonance imaging (MRI)

    Brain imaging using MRI is a technique used to measure cortical thickness by capturing high-resolution images of brain structures. Participants lie in an MRI scanner for approximately 10 to 20 minutes during data acquisition. After the scan, the images are processed using FreeSurfer software. Cortical thickness is calculated by measuring the distance between the white matter surface and the outer surface of the cerebral cortex.

    Measured: Brain imaging using MRI will be measured at three time points (baseline, 3-month and 6-month post intervention).

  11. Compound muscle action potential (CMAP)

    To record Compound Muscle Action Potential (CMAP), electrical stimulation is applied to the nerve, gradually increasing the intensity step by step. The muscle responses are recorded to determine the maximum CMAP response, which is achieved at supramaximal stimulation. CMAP is a key parameter in studies related to nerve conduction and provides important information about motor neuron function. A higher CMAP value indicates greater muscle fiber activation, which reflects the number of functional motor units still intact.

    Measured: CMAP will be meausred at three time points (baseline, 3-month, and 6-month post intervention).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jul 2025
  2. Study start1 Aug 2025
  3. Primary completion30 Aug 2027 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07067229
Sponsor's protocol ID
COA No. 1142/2024
Status last verified
Jul 2025
First submitted
5 Jul 2025
Last updated
25 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Personalized rTMS and Standard rTMS in people with ALS (Amyotrophic Lateral Sclerosis), run by Chulalongkorn University at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jakkrit Amornvit, MD (Thailand: 88-951-9195, jakkrit.a@chula.ac.th), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Amyotrophic Lateral Sclerosis Functional rating scale - revised version (ALSFRS-R) (time frame: ALSFRS-R will be measured at three time points (baseline, 3-month, and 6-month post intervention).). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in